Hillevax, Inc. (HLVX)

$1.75

+0.08

(+4.79%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Hillevax, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 169.8%

Performance

  • $1.67
    $1.78
    $1.75
    downward going graph

    4.86%

    Downside

    Day's Volatility :6.46%

    Upside

    1.69%

    downward going graph
  • $1.60
    $20.22
    $1.75
    downward going graph

    8.57%

    Downside

    52 Weeks Volatility :92.09%

    Upside

    91.35%

    downward going graph

Returns

PeriodHillevax, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-88.89%
6.1%
0.0%
6 Months
-88.78%
4.9%
0.0%
1 Year
-89.13%
13.6%
0.0%
3 Years
-91.25%
14.3%
-22.5%

Highlights

Market Capitalization
81.0M
Book Value
$5.03
Earnings Per Share (EPS)
-3.3
Wall Street Target Price
2.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.22%
Return On Equity TTM
-59.55%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-137.5M
Diluted Eps TTM
-3.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.76
EPS Estimate Next Year
-1.68
EPS Estimate Current Quarter
-0.84
EPS Estimate Next Quarter
-0.87

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Hillevax, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 33.14%

Current $1.75
Target $2.33

Technicals Summary

Sell

Neutral

Buy

Hillevax, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hillevax, Inc.
Hillevax, Inc.
-88.56%
-88.78%
-89.13%
-91.25%
-91.25%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hillevax, Inc.
Hillevax, Inc.
NA
NA
NA
-2.76
-0.6
-0.28
NA
5.03
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hillevax, Inc.
Hillevax, Inc.
Buy
$81.0M
-91.25%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • Deerfield Management Co

    8.05%
  • T. Rowe Price Investment Management,Inc.

    6.16%
  • Deep Track Capital, LP

    5.17%
  • VR Adviser, LLC

    4.17%
  • Franklin Resources Inc

    3.73%
  • The Carlyle Group Inc

    3.70%

Company Information

hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Organization
Hillevax, Inc.
Employees
90
CEO
Dr. Robert M. Hershberg M.D., Ph.D.
Industry
Services

FAQs